The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers. / Tan, Tricia; Behary, Preeshila; Tharakan, George; Minnion, James; Al-Najim, Werd; Wewer Albrechtsen, Nicolai J; Holst, Jens J; Bloom, Stephen R.

I: The Journal of clinical endocrinology and metabolism, Bind 102, Nr. 7, 01.07.2017, s. 2364-2372.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Tan, T, Behary, P, Tharakan, G, Minnion, J, Al-Najim, W, Wewer Albrechtsen, NJ, Holst, JJ & Bloom, SR 2017, 'The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers', The Journal of clinical endocrinology and metabolism, bind 102, nr. 7, s. 2364-2372. https://doi.org/10.1210/jc.2017-00469

APA

Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Wewer Albrechtsen, N. J., Holst, J. J., & Bloom, S. R. (2017). The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers. The Journal of clinical endocrinology and metabolism, 102(7), 2364-2372. https://doi.org/10.1210/jc.2017-00469

Vancouver

Tan T, Behary P, Tharakan G, Minnion J, Al-Najim W, Wewer Albrechtsen NJ o.a. The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers. The Journal of clinical endocrinology and metabolism. 2017 jul. 1;102(7):2364-2372. https://doi.org/10.1210/jc.2017-00469

Author

Tan, Tricia ; Behary, Preeshila ; Tharakan, George ; Minnion, James ; Al-Najim, Werd ; Wewer Albrechtsen, Nicolai J ; Holst, Jens J ; Bloom, Stephen R. / The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers. I: The Journal of clinical endocrinology and metabolism. 2017 ; Bind 102, Nr. 7. s. 2364-2372.

Bibtex

@article{22ebce3ec0714fa9bfd5643cea59cb4a,
title = "The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers",
abstract = "Background: Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective treatment for obesity, although limited by availability and operative risk. The gut hormones Glucagon-like peptide-1 (GLP-1), Peptide YY (PYY) and Oxyntomodulin (OXM) are elevated post-prandially after RYGB, which has been postulated to contribute to its metabolic benefits.Objective: We hypothesised that infusion of the three gut hormones to achieve levels similar to those encountered post-prandially in RYGB patients might be effective in suppressing appetite. The aim of this study was to investigate the effect of a continuous infusion of GLP-1, OXM and PYY (GOP) on energy intake and expenditure in obese volunteers.Methods: Obese volunteers were randomised to receive an infusion of GOP or placebo in a single-blinded randomised placebo-controlled cross-over study for 10.5 hours a day. This was delivered subcutaneously using a pump device, allowing volunteers to remain ambulatory. Ad Libitum food intake studies were performed during the infusion and energy expenditure measured using a ventilated hood calorimeter.Results: Post-prandial levels of GLP-1, OXM and PYY seen post RYGB were successfully matched using 4 pmol/kg/min, 4 pmol/kg/min and 0.4 pmol/kg/min respectively. This dose led to a mean reduction of 32% in food intake. No significant effects on resting energy expenditure were observed.Conclusion: This is the first time that an acute continuous subcutaneous infusion of GOP, replicating the post-prandial levels observed after RYGB, is shown to be safe and effective in reducing food intake. This data suggests that triple hormone therapy might be a useful tool against obesity.",
keywords = "Journal Article",
author = "Tricia Tan and Preeshila Behary and George Tharakan and James Minnion and Werd Al-Najim and {Wewer Albrechtsen}, {Nicolai J} and Holst, {Jens J} and Bloom, {Stephen R}",
year = "2017",
month = jul,
day = "1",
doi = "10.1210/jc.2017-00469",
language = "English",
volume = "102",
pages = "2364--2372",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - The effect of a subcutaneous infusion of GLP-1, OXM and PYY on Energy intake and Expenditure in Obese volunteers

AU - Tan, Tricia

AU - Behary, Preeshila

AU - Tharakan, George

AU - Minnion, James

AU - Al-Najim, Werd

AU - Wewer Albrechtsen, Nicolai J

AU - Holst, Jens J

AU - Bloom, Stephen R

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective treatment for obesity, although limited by availability and operative risk. The gut hormones Glucagon-like peptide-1 (GLP-1), Peptide YY (PYY) and Oxyntomodulin (OXM) are elevated post-prandially after RYGB, which has been postulated to contribute to its metabolic benefits.Objective: We hypothesised that infusion of the three gut hormones to achieve levels similar to those encountered post-prandially in RYGB patients might be effective in suppressing appetite. The aim of this study was to investigate the effect of a continuous infusion of GLP-1, OXM and PYY (GOP) on energy intake and expenditure in obese volunteers.Methods: Obese volunteers were randomised to receive an infusion of GOP or placebo in a single-blinded randomised placebo-controlled cross-over study for 10.5 hours a day. This was delivered subcutaneously using a pump device, allowing volunteers to remain ambulatory. Ad Libitum food intake studies were performed during the infusion and energy expenditure measured using a ventilated hood calorimeter.Results: Post-prandial levels of GLP-1, OXM and PYY seen post RYGB were successfully matched using 4 pmol/kg/min, 4 pmol/kg/min and 0.4 pmol/kg/min respectively. This dose led to a mean reduction of 32% in food intake. No significant effects on resting energy expenditure were observed.Conclusion: This is the first time that an acute continuous subcutaneous infusion of GOP, replicating the post-prandial levels observed after RYGB, is shown to be safe and effective in reducing food intake. This data suggests that triple hormone therapy might be a useful tool against obesity.

AB - Background: Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective treatment for obesity, although limited by availability and operative risk. The gut hormones Glucagon-like peptide-1 (GLP-1), Peptide YY (PYY) and Oxyntomodulin (OXM) are elevated post-prandially after RYGB, which has been postulated to contribute to its metabolic benefits.Objective: We hypothesised that infusion of the three gut hormones to achieve levels similar to those encountered post-prandially in RYGB patients might be effective in suppressing appetite. The aim of this study was to investigate the effect of a continuous infusion of GLP-1, OXM and PYY (GOP) on energy intake and expenditure in obese volunteers.Methods: Obese volunteers were randomised to receive an infusion of GOP or placebo in a single-blinded randomised placebo-controlled cross-over study for 10.5 hours a day. This was delivered subcutaneously using a pump device, allowing volunteers to remain ambulatory. Ad Libitum food intake studies were performed during the infusion and energy expenditure measured using a ventilated hood calorimeter.Results: Post-prandial levels of GLP-1, OXM and PYY seen post RYGB were successfully matched using 4 pmol/kg/min, 4 pmol/kg/min and 0.4 pmol/kg/min respectively. This dose led to a mean reduction of 32% in food intake. No significant effects on resting energy expenditure were observed.Conclusion: This is the first time that an acute continuous subcutaneous infusion of GOP, replicating the post-prandial levels observed after RYGB, is shown to be safe and effective in reducing food intake. This data suggests that triple hormone therapy might be a useful tool against obesity.

KW - Journal Article

U2 - 10.1210/jc.2017-00469

DO - 10.1210/jc.2017-00469

M3 - Journal article

C2 - 28379519

VL - 102

SP - 2364

EP - 2372

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -

ID: 183005801